✦ LIBER ✦

P4-382: Effectiveness and safety of donepezil in Hispanic patients with mild to moderate Alzheimer's disease: A 12-week open-label study

✍ Scribed by Lopez, Oscar L.; Mackell, Joan A.; Sun, Yijun; Kassalow, Laurent M.; Xu, Yikang; Li, Honglan

Book ID: 122075632
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 57 KB
Volume: 4
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2008.05.2452

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy of donepezil in a 12

Safety and efficacy of donepezil in a 12-week, open-label trial in African Americans with mild to moderate Alzheimer’s disease

✍ Patrick Griffith; Peter Lichtenberg; Robert Goldman; Lynn Burger; June Lato; Jen 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 61 KB

A multinational, randomised, 12-week stu

A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

✍ Roy W. Jones; Hilkka Soininen; Klaus Hager; Dag Aarsland; Peter Passmore; Anita 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

## Abstract ## Objectives To compare directly, in the same patient cohort, the ease of use and tolerability of donepezil and galantamine in the treatment of Alzheimer's disease (AD), and investigate the effects of both treatments on cognition and activities of daily living (ADL). ## Methods Pati

Open label, multicenter, 28-week extensi

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease

✍ Brian R. Ott; Lesley M. Blake; Ethel Kagan; Malca Resnick; for the Memantine MEM 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 142 KB

P.5.a.006 Long-term safety and tolerabil

P.5.a.006 Long-term safety and tolerability of memantine: an open-label extension study in patients with mild to moderate Alzheimer's disease

✍ S. Bakchine; M. Rainer 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Disease progression in patients with mil

Disease progression in patients with mild-to-moderate Alzheimer's disease treated with galantamine: Results of a two-year open-label study

✍ Gaudig, Maren; Richarz, Ute; Rettig, Klaus; Djelani, Miriam; Schauble, Barbara 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Efficacy and safety of donepezil over 3

Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease

✍ A. Burns; S. Gauthier; C. Perdomo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

## Abstract ## Objective This 132‐week, open‐label extension study assessed the long‐term efficacy and safety of donepezil in 579 patients with mild to moderate Alzheimer's disease (AD) who had previously participated in a 24‐week double‐blind study of 5 or 10 mg/day donepezil __vs__ placebo. ##